Tibolone: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
| routes_of_administration= oral |
| routes_of_administration= oral |
||
}} |
}} |
||
'''Tibolone''' is a synthetic [[steroid hormone]] drug, which is fairly non-selective in its binding profile, acting as an [[agonist]] at all five of the Type I [[steroid hormone receptor]]s.<ref name="pmid19464167">{{cite journal |author=Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T |title=Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites |journal=The Journal of Steroid Biochemistry and Molecular Biology |volume=116 |issue=1-2 |pages=8–14 |year=2009 |month=August |pmid=19464167 |doi=10.1016/j.jsbmb.2009.03.008 |url=}}</ref> It is used mainly for [[hormone replacement therapy]] in [[menopause|post-menopausal]] women.<ref name="pmid19317264">{{cite journal |author=Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN |title=Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists |journal=European Journal of Gynaecological Oncology |volume=30 |issue=1 |pages=82–4 |year=2009 |pmid=19317264 |doi= |url=}}</ref> |
'''Tibolone''' is a synthetic [[steroid hormone]] drug, which is fairly non-selective in its binding profile, acting as an [[agonist]] at all five of the Type I [[steroid hormone receptor]]s.<ref name="pmid19464167">{{cite journal |author=Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T |title=Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites |journal=The Journal of Steroid Biochemistry and Molecular Biology |volume=116 |issue=1-2 |pages=8–14 |year=2009 |month=August |pmid=19464167 |doi=10.1016/j.jsbmb.2009.03.008 |url=}}</ref> It is used mainly for treatment of [[endometriosis]],<ref name="pmid19160262">{{cite journal |author=Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A |title=Hormone therapy for endometriosis and surgical menopause |journal=Cochrane Database of Systematic Reviews (Online) |volume= |issue=1 |pages=CD005997 |year=2009 |pmid=19160262 |doi=10.1002/14651858.CD005997.pub2 |url=}}</ref> as well as [[hormone replacement therapy]] in [[menopause|post-menopausal]] women. Tibolone has similar or greater efficacy compared to older hormone replacement drugs, but shares a similar side effect profile.<ref name="pmid18377345">{{cite journal |author=Lazovic G, Radivojevic U, Marinkovic J |title=Tibolone: the way to beat many a postmenopausal ailments |journal=Expert Opinion on Pharmacotherapy |volume=9 |issue=6 |pages=1039–47 |year=2008 |month=April |pmid=18377345 |doi=10.1517/14656566.9.6.1039 |url=}}</ref><ref name="pmid18488873">{{cite journal |author=Garefalakis M, Hickey M |title=Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence |journal=Clinical Interventions in Aging |volume=3 |issue=1 |pages=1–8 |year=2008 |pmid=18488873 |pmc=2544356 |doi= |url=}}</ref><ref name="pmid19317264">{{cite journal |author=Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN |title=Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists |journal=European Journal of Gynaecological Oncology |volume=30 |issue=1 |pages=82–4 |year=2009 |pmid=19317264 |doi= |url=}}</ref> |
||
==References== |
==References== |
||
Revision as of 05:43, 9 August 2009
 | |
| Clinical data | |
|---|---|
| Other names | 17-Hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one |
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.024.609 |
| Chemical and physical data | |
| Formula | C21H28O2 |
| Molar mass | 312.446 g/mol g·mol−1 |
Tibolone is a synthetic steroid hormone drug, which is fairly non-selective in its binding profile, acting as an agonist at all five of the Type I steroid hormone receptors.[1] It is used mainly for treatment of endometriosis,[2] as well as hormone replacement therapy in post-menopausal women. Tibolone has similar or greater efficacy compared to older hormone replacement drugs, but shares a similar side effect profile.[3][4][5]
References
- ^ Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites". The Journal of Steroid Biochemistry and Molecular Biology. 116 (1–2): 8–14. doi:10.1016/j.jsbmb.2009.03.008. PMID 19464167.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A (2009). "Hormone therapy for endometriosis and surgical menopause". Cochrane Database of Systematic Reviews (Online) (1): CD005997. doi:10.1002/14651858.CD005997.pub2. PMID 19160262.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Lazovic G, Radivojevic U, Marinkovic J (2008). "Tibolone: the way to beat many a postmenopausal ailments". Expert Opinion on Pharmacotherapy. 9 (6): 1039–47. doi:10.1517/14656566.9.6.1039. PMID 18377345.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clinical Interventions in Aging. 3 (1): 1–8. PMC 2544356. PMID 18488873.
- ^ Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN (2009). "Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists". European Journal of Gynaecological Oncology. 30 (1): 82–4. PMID 19317264.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |